PRODUCT INFORMATION



ANGPTL3 (human) Monoclonal Antibody (Clone Kairos-37)

Item No. 10805

Overview and Properties

This vial contains a 1 mg/ml solution in PBS, pH 7.4. Contents:

Synonyms: Angiopoietin-5, Angiopoietin-like 3, Angiopoietin-related Protein 3, ANG-5

Immunogen: Recombinant human ANGPTL3

Cross Reactivity: (-) Human ANGPTL isoforms 1, 2, 4, 6, and 7

Species Reactivity: (+) Human ANGPTL3 -20°C (as supplied) Storage: Stability: ≥6 months


Clone: Kairos-37 Host: Mouse Isotype: IgG1ĸ

ELISA and Western blot (WB); the recommended starting dilution is 1:1,000-1:5,000 Applications:

for ELISA and 1:2,000-1-5,000 for WB. Other applications were not tested, therefore

optimal working concentration/dilution should be determined empirically.

Image



Lane 1: Recombinant ANGPTL3 (human)

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/11/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Angiopoietin-like 3 (ANGPTL3) is an angiopoietin-related protein involved in lipid metabolism.^{1,2} It is composed of a signal peptide, coiled-coil domain, linker region, and C-terminal fibrinogen-like domain.^{2,3} ANGPTL3 is expressed in adult liver and during embryonic development.³ It inhibits the activity of lipoprotein lipase and endothelial lipase, which increases plasma triglycerides and HDL-cholesterol (HDL-C) levels.⁴⁻⁶ Loss-of-function mutations in ANGPTL3 are associated with decreased risk of coronary artery disease, coronary atherosclerosis, or myocardial infarction.⁶ Formulations containing monoclonal antibodies targeting ANGPTL3 have been used in the treatment of homozygous familial hypercholesterolemia. Cayman's ANGPTL3 (human) Monoclonal Antibody (Clone Kairos-37) can be used for ELISA and Western blot (WB) applications. The antibody recognizes ANGPTL3 at approximately 68 kDa and a cleaved band of approximately 35 kDa from human samples.

References

- 1. Kadomatsu, T., Tabata, M., and Oike, Y. Angiopoietin-like proteins: Emerging targets for treatment of obesity and related metabolic diseases. *FEBS J.* **278(4)**, 559-564 (2011).
- 2. Oike, Y., Akao, M., Kubota, Y., et al. Angiopoietin-like proteins: Potential new targets for metabolic syndrome therapy. *Trends Mol. Med.* **11(10)**, 473-479 (2005).
- 3. Conklin, D., Gilbertson, D., Taft, D.W., et al. Identification of a mammalian angiopoietin-related protein expressed specifically in liver. *Genomics* **62(3)**, 477-482 (1999).
- 4. Shan, L., Yu, X.C., Liu, Z., et al. The Angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J. Biol. Chem. 284(3), 1419-1424 (2009).
- 5. Shimamura, M., Matsuda, M., Yasumo, H., et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 27(2), 366-372 (2007).
- 6. Luo, F., Das, A., Khetarpal, S.A., et al. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Trends Cardiovasc. Med. 34(4), 215-222 (2024).

ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897